Fig. 3From: Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patientsScatterplot of vilobelimab concentration at hospital discharge by time from last vilobelimab infusionBack to article page